Jonathan Sackner Bernstein

Jonathan Sackner Bernstein
Sackner Bernstein in 2016.
Born	(1961-01-27)January 27, 1961 Philadelphia, PA
Nationality	American
Alma mater	University of Pennsylvania Moore School of Electrical Engineering Jefferson Medical College
Occupation	Cardiologist
Organization	Mt. Sinai Hospital Columbia University Food and Drug Administration SRD Med
Known for	Medical Product Regulation, Clinical Research
Spouse(s)	Audrey Sackner Bernstein

Jonathan Sackner Bernstein (born 27 January 1961) is an American physician, researcher, and administrator. He has published more than 80 scientific articles, which have been cited more than 4,000 times...^[1] His research has ranged from cardiac care to the efficacy of drugs. His research led to increased scrutiny of Nesiritide, a widely marketed drug, which led to its decline in the marketplace.^[2]

Education

Sackner Bernstein graduated from the University of Pennsylvania's Moore School of Electrical Engineering in 1983 (BSEE), where he was president of Eta Kappa Nu, the electrical engineering honor society. He completed his MD from Jefferson Medical College, during which he moonlit writing code.^[3] He completed a residency in internal medicine and subsequently cardiology at Mount Sinai Hospital in New York. In addition, Sackner Bernstein completed a research fellowship in heart failure under Milton Packer, MD at Mount Sinai.^[4]

Academic, clinical and research experience

Bernstein joined the Columbia University faculty in 1993 in the Division of Circulatory Physiology, where he established its clinical research program. As a clinical investigator, he accumulated a large experience with the beta-blocker carvedilol prior to the application by its developer (GlaxoSmithKline) to the US Food and Drug Administration (FDA).^[5]

Bernstein's most cited research focused on whether the newly marketed heart failure drug nesiritide (hr-BNP, Natrecor) was safe and effective, with a call for large-scale clinical trials prior to widespread use.^[6][7][8] While nesiritide was projected to generate $1 billion in sales in 2006,^[9] these studies triggered controversy^[10] that eventually led to markedly lower use by physicians.^[11]

Other frequently cited articles include work on Carvedilol ^[12] and cardiac hypertrophy ^[13]

He is also the author of a book on heart disease, Before It Happens To You^[14]

US government projects

Bernstein joined the FDA in 2008 as Associate Center Director, leading Post Market Operations as well as Technology and Innovation programs.^[15]

He also helped establish a formal relationship between FDA and DARPA (Defense Advanced Research Projects Agency),^[16] then serving as architect for the initial White House Office of Science and Technology Policy (OSTP) sponsored Entrepreneurs-in-Residence Program.^[17]

Commercial projects

Sackner Bernstein launched SRD Med, LLC in 2015.

References